x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

OncoPharm

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

science

All Episodes

00:11:30

Dordaviprone & RCT to prevent ADRs

OncoPharm ·

2025/08/07

This week's episode discusses the first-in-class agent, dordaviprone and a randomized control trial that demonstrated an oncology pharmacists led to decreased rates of adverse drug reactions (ADRs) in a Hem/Onc clinic.Dordaviprone data: https://doi.org/10.1200/jco.23.01134 Alabassi AK, et al. Role of a designated pharmacist in reducing adverse drug reaction rates and preventing potential medication errors in hematology-oncology: a randomized controlled trial. JCO Oncology Practice:

en

00:10:21

ProMACE-CytaBOM

OncoPharm ·

2025/07/31

More isn't always better. Our Landkmarks of OncoPharm series covers lessons learned from the ProMACE-CytaBOM regimen for NHL.ProMACE-CytaBOM: https://www.annalsofoncology.org/article/S0923-7534(20)31592-1/pdf RCT vs. CHOP (& others): https://www.nejm.org/doi/full/10.1056/NEJM199304083281404

en

00:11:19

Testicular Cancer in a Nutshell

OncoPharm ·

2025/07/17

A brief overview of testicular cancer

en

00:11:12

Supportive Care Updates

OncoPharm ·

2025/07/10

A few supportive care updates:1. Skin prophylaxis to prevent severe dermatologic toxicity with Nivo/Ipi. Note* published in JCO Oncology Practice (NOT JAMA Oncol as stated in the episode Link: https://doi.org/10.1200/OP-25-00100 2. Stampede-Metformin and how metformin has some beneficial effects in prostate cancer patients who don't have diabetes Link: https://doi.org/10.1016/S1470-2045(25)00231-1

en

00:09:36

Linvoseltamab & sunvozertinib

OncoPharm ·

2025/07/03

Two new drug approvals to talk about (after I misplaced my notes!)

en

00:09:53

Antiandrogen Withdrawal

OncoPharm ·

2025/06/25

Antiandrogen withdrawal is an historically well described phenomenon where prostate cancer patients experience PSA responses AFTER stopping their anti-androgen. But does this happen with today's 2nd generation antiandrogens?

en

00:27:37

June 2025 Updates

OncoPharm ·

2025/06/19

A plethora of recent updates:-Pembrolizumab (perioperative) in head & neck cancer (Keynote-689) -Prostate cancer updates on cabozantinib/atezolizumab (yes, really) and talazoparib -Pirtobrutinib improves PFS in CLL -Zanubrutinib has a new dosage form on the way -Another mitomycin product approved with "reverse thermal properties" -A new regimen for FL of tafasitamab/rituximab/lenalidomide -A comparison of the new ROS1-inhibitor, taltrectenib, compared to other 1st-line treatment options

en

00:14:15

ASCO 2025

OncoPharm ·

2025/06/05

A recap of notable updates from ASCO 20251. Destiny-Breast09 2. BREAKWATER 3. ATOMIC 4. Delphi-304 5. CM 816 OS update 6. C-POST 7. Matterhorn

en

00:11:17

CLEOPATRA

OncoPharm ·

2025/05/29

Our Landmarks of OncoPharm series returns to discuss the CLEOPATRA study, which established docetaxel, trastuzumab, pertuzumab (THP) as a standard first-line regimen for metastatic HER2-amplified breast cancer.

en

00:15:27

Talking about cancer misinformation

OncoPharm ·

2025/05/22

If you've been struggling with how to talk to patients about ivermectin for cancer, then this podcast is for you.1. Cancer misinformation on social media (Loeb, et al): https://doi.org/10.3322/caac.21857 2. Clinician communication with patients about cancer misinformation (Bylund, et al): https://doi.org/10.1200/OP.22.00526

en

00:12:20

Four New Drugs

OncoPharm ·

2025/05/22

Discussing recent FDA approvals of penpulimab, avutometenib, defactinib, and telisotuzumab vedotin.

en

00:15:48

Mg to Prevent Cisplatin Kidney Injury

OncoPharm ·

2025/05/08

A splashy large study and two small studies suggest IV Mg in pre-hydration fluids can decrease the risk of cisplatin kidney injury.Gupta et al. JAMA Oncol (2025): doi:10.1001/jamaoncol.2025.0756 PRAGMATIC. ESMO Open (2022): https://doi.org/10.1016/j.esmoop.2021.100351 Yamamoto et al. Anticancer Res (2015): https://pubmed.ncbi.nlm.nih.gov/25862878/

en

00:12:11

TI-CH, Updates on dostarlimab, ventoclax, & zongertinib

OncoPharm ·

2025/05/01

This episode summarizes recent updates on:Tumor infiltrating clonal hematopoiesis (TI-CH) and its apparent negative impact on solid tumors (https://www.nejm.org/doi/full/10.1056/NEJMoa2413361) Updated dostarlimab data on MMRd use in rectal cancer and other solid tumors in the neoadjuvant (definitive?!?!) setting (https://www.nejm.org/doi/full/10.1056/NEJMoa2404512) Phase 1 study of 7 + 3 + Venetoclax (https://doi.org/10.1182/blood.2024026700) Zongertinib, a new HER2 TKI

en

00:12:43

BRCA Reversion Mutations

OncoPharm ·

2025/04/24

BRCA revision mutations may explain some of the limited benefit seen in long-term follow-up studies with PARP inhibitors.Bibliography: 1: BRCA reversion mutations predict resistance. https://doi.org/10.1158/2159-8290.CD-18-0715 2: SOLO3 Final OS Data. https://doi.org/10.1200/JCO.24.00933 3: Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. https://doi.org/10.1016/j.ccell.2024.10.015

en

00:11:45

HOPA 25 Recap

OncoPharm ·

2025/04/17

Recapping HOPA 25 and Portland*Great food (not discussed, the most excellent ETSU dinner at Arden) *COCOON *Pharmacists make everyone's job easier and keep patients out of the ED *A few more tidbits too!

en

00:12:25

Expanded Approvals for Durvalumab, Lu 177 vt;...

OncoPharm ·

2025/04/08

FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.

en

00:12:42

API-CAT & IMPROVE

OncoPharm ·

2025/04/03

We discuss reduced dose apixaban for months 6+ of treating cancer-associated VTE (API-CAT) and the impact (or lack thereof) of pausing BTK-inhibitors around vaccination (IMPROVE)

en

00:09:46

Topotecan

OncoPharm ·

2025/04/03

A Foundations of OncoPharm episode on Topotecan. (Originally to be released week of 3/27)

en

00:12:59

Keynote 811 Update

OncoPharm ·

2025/03/19

The updated Keynote 811 OS results convert an accelerated approval for pembrolizumab to a regular approval, albeit restricted by PD-L1 CPS status of 1 or higher.

en

00:09:59

Polar: Cryotherapy or Compression to Prevent...

OncoPharm ·

2025/03/13

There is a decent track record with mixed results for cryotherapy to prevent taxane-induced peripheral neuropathy. The POLAR trial adds to this body of evidence that trends in favor of cryotherapy. Compression therapy is another alternative. Both are studied in POLAR.POLAR: doi:10.1001/jamaoncol.2025.0001

en

409 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter